ClinicalTrials.gg
CompletedNCT00835991Updated Aug 19, 2024Results posted

Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed

A Phase 1 interventional study of Glyburide/Metformin 5 mg/500 mg Tablets and Glucovance® 5 mg/500 mg Tablets in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare the rate and extent of absorption of Glyburide/Metformin 5 mg/500 mg film-coated tablets (test) versus Glucovance® (reference) administered as 1 x 5 mg/500 mg film-coated tablet under fed conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be females and/or males, non-smokers, 18 years of age and older.

Exclusion criteria

Exclusion Criteria:

  • illnesses within 4 weeks of the administration of study medication.
  • Clinically significant surgery within 4 weeks prior to the administration of the study medication.
  • Any clinically significant abnormality found during medical screening.
  • Any reason which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
  • Abnormal laboratory tests judged clinically significant.
  • Positive urine drug screen at screening.
  • Positive testing for , or at screening.
  • Subjects with less than or equal to 30.0.
  • History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than fourteen units of alcohol per week (1 Unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).
  • History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year of the screening visit.
  • History of allergic reactions to glyburide or to metformin or other related drugs (e.g. chlorpropamide, gliclazide, tolbutamide, furosemide, sulfamethoxazole, sulfadiazine and sulfisoxazole).
  • Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, , rifampin/rifabutin; examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior to administration of the study medication.
  • Use of an drug or participation in an investigational study within 30 days prior to administration of the study medication.
  • History or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug.
  • Any history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
  • Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins, garlic as supplement) within 7 days prior to administration of study medication except for topical products without systemic absorption.
  • Positive alcohol breath test at screening. subjects who have used tobacco in any form within the 90 days preceding study drug administration.
  • Intolerance to venipuncture.
  • Any food allergy, intolerance, restriction, or special diet that, in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study.
  • Subjects who have had a depot injection or an implant of any drug 3 months prior to administration of study medication.
  • Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to administration of the study medication as follows: less than 300 mL of whole blood within 30 days or; 300 mL to 500 mL of whole blood within 45 days or; more than 500 mL of whole blood within 56 days.
  • Subjects with a clinically significant history of tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible for this study.
  • History of metabolic acidosis, congestive heart failure and myocardial infarction.
  • Breast-feeding subjects.
  • Positive urine pregnancy test at screening (performed on all females).
  • Female subjects of who have had unprotected sexual intercourse with any non-steril male partner (i.e. male who has not been sterilized by vasectomy for at least 6 months) within 14 days prior to study drug administration. The acceptable methods of are:

    1. Condom + spermicide
    2. Diaphragm + spermicide
    3. Intrauterine contraceptive device (placed at least 4 weeks prior to study drug administration)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Glyburide Metformin

    Glyburide Metformin 5/500 Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period

    Drug: Glyburide/Metformin 5 mg/500 mg Tablets

  • Active comparator
    Glucovance®

    Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period

    Drug: Glucovance® 5 mg/500 mg Tablets

Interventions

  • DrugGlyburide/Metformin 5 mg/500 mg Tablets

    Drug pages: Glyburide · Metformin

    1 x 5 mg/500 mg, single-dose fed

  • DrugGlucovance® 5 mg/500 mg Tablets

    Drug page: Glucovance

    1 x 5 mg/500 mg, single-dose fed

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Concentration) - Glyburide

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 36 hour period

  2. AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Glyburide

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 36 hour period

  3. AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Glyburide

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 36 hour period

  4. Cmax (Maximum Observed Concentration) - Metformin

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 36 hour period

  5. AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Metformin

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 36 hour period

  6. AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Metformin

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 36 hour period

07

Results

Posted Aug 4, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneGlyburide Metformin (Test) FirstGlucovance® (Reference) First
Started3030
Completed3029
Not completed01
Withdrew: Adverse event01
Washout
Participant flow — Washout
MilestoneGlyburide Metformin (Test) FirstGlucovance® (Reference) First
Started3029
Completed2726
Not completed33
Withdrew: Protocol violation02
Withdrew: Withdrawal by subject31
Second Intervention
Participant flow — Second Intervention
MilestoneGlyburide Metformin (Test) FirstGlucovance® (Reference) First
Started2726
Completed2726
Not completed00

Outcome measures

PrimaryCmax (Maximum Observed Concentration) - Glyburide

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng/mL
Cmax (Maximum Observed Concentration) - Glyburide
ng/mLGlyburide MetforminGlucovance®
Cmax (Maximum Observed Concentration) - Glyburide190.17 ± 68.08166.48 ± 59.87
Statistical analysis
  • Glyburide Metformin vs Glucovance® · Test/ref ratio of ls means x 100: 114.05 · 90% CI 107.26 to 121.27Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Glyburide

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng*h/mL
AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Glyburide
ng*h/mLGlyburide MetforminGlucovance®
AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Glyburide970.22 ± 328.93977.28 ± 402.74
Statistical analysis
  • Glyburide Metformin vs Glucovance® · Test/ref ratio of ls means x 100: 100.63 · 90% CI 97.59 to 103.76Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Glyburide

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng*h/mL
AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Glyburide
ng*h/mLGlyburide MetforminGlucovance®
AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Glyburide942.94 ± 316.17943.45 ± 388.26
Statistical analysis
  • Glyburide Metformin vs Glucovance® · Test/ref ratio of ls means x 100: 101.36 · 90% CI 98.32 to 104.48Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryCmax (Maximum Observed Concentration) - Metformin

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng/mL
Cmax (Maximum Observed Concentration) - Metformin
ng/mLGlyburide MetforminGlucovance®
Cmax (Maximum Observed Concentration) - Metformin755.10 ± 195.97766.30 ± 210.22
Statistical analysis
  • Glyburide Metformin vs Glucovance® · Test/ref ratio of ls means x 100: 99.05 · 90% CI 94.31 to 104.02Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Metformin

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng*h/mL
AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Metformin
ng*h/mLGlyburide MetforminGlucovance®
AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Metformin6308.12 ± 1662.696552.79 ± 1833.42
Statistical analysis
  • Glyburide Metformin vs Glucovance® · Test/ref ratio of ls means x 100: 96.55 · 90% CI 93.85 to 99.32Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Metformin

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng*h/mL
AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Metformin
ng*h/mLGlyburide MetforminGlucovance®
AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Metformin6203.57 ± 1656.576448.34 ± 1814.06
Statistical analysis
  • Glyburide Metformin vs Glucovance® · Test/ref ratio of ls means x 100: 96.44 · 90% CI 93.71 to 99.25Bioequivalence is established when 90% Confidence Interval falls within 80-125.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Glyburide Metformin (Test) FirstGlucovance® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years262854
>=65 years426
Sex: Female, Male
Sex: Female, Male(Participants)Glyburide Metformin (Test) FirstGlucovance® (Reference) FirstTotal
Female101020
Male202040
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Glyburide Metformin (Test) FirstGlucovance® (Reference) FirstTotal
Caucasian242751
American Hispanic426
Black213
Region of Enrollment
Region of Enrollment(participants)Glyburide Metformin (Test) FirstGlucovance® (Reference) FirstTotal
Canada303060
08

Study locations

1 site
  • Anapharm Inc.
    Sainte-Foy, Quebec GIV2K8, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Feb 2003 and a completion of Feb 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2009
First posted
Feb 4, 2009
Start
Feb 2003
Primary completionActual
Feb 2003
CompletionActual
Feb 2003
Results first posted
Aug 4, 2009
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00835991
First posted
Feb 4, 2009
Start date
Feb 2003
Primary completion
Feb 2003
Completion
Feb 2003
Results posted
Aug 4, 2009
Last update
Aug 19, 2024

Study contacts

Eric Bicrell, M.D.
principal investigator · Anapharm

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glyburide · Metformin

Start the discussion